ArticleDiscover oncology2026
A nomogram model based on dual-center data predicts lymph node metastasis in endometrial cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThe role of lymphadenectomy in endometrial cancer management remains controversial. This study aimed to identify clinicopathological characteristics and serum tumor markers that predict lymph node metastasis (LNM), and to develop a nomogram model integrating these parameters to predict individual LNM risk and guide personalized surgical planning.
methodsRetrospective analysis was conducted on clinicopathological data and serum tumor marker levels for endometrial cancer patients who underwent surgical staging, including total hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy with or without para-aortic lymphadenectomy, at the Third Affiliated Hospital of Nanjing Medical University and Shanghai East Hospital of Tongji University from January 2008 to December 2024. Independent predictors of LNM were determined through univariate and multivariate logistic regression analyses and optimal subset selection. A nomogram model was developed using these variables. Predictive performance and accuracy were evaluated via receiver operating characteristic (ROC) curves and calibration plots.
resultsAmong 506 eligible patients, 39 (7.7%) had LNM. Multivariate logistic regression and optimal subset analysis identified ovarian invasion (OR: 33.233, 95% CI 8.322–132.708), depth of myometrial invasion (OR: 27.223, 95% CI 10.989–67.436, P < 0.001), LVSI (OR: 13.129, 95% CI 6.191–27.841, P < 0.001), histological grade (OR: 2.933, 95% CI 1.800–4.778, P < 0.001), and CA199 levels (OR: 1.005, 95% CI 1.002–1.009, P < 0.004) as independent predictors of LNM. The nomogram demonstrated an AUC of 0.9106 (95% CI 0.8643–0.9569), specificity of 0.7923, sensitivity of 0.8974, accuracy of 0.8084, and negative predictive value of 0.9893. Calibration analysis showed strong agreement between predicted and observed outcomes. Decision curve analysis (DCA) indicated that the model offered clinical benefit.
conclusionThe nomogram provides accurate LNM risk stratification in endometrial cancer, serving as a valuable tool to optimize lymphadenectomy strategies based on individual risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.